# MediGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medigene

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.medigene.com
- Total disclosed funding: $26M
- Latest round: Series C (Sep 1, 1998)
- Investors on record: 8

## About

Based in Martinsried, Germany, and founded in 1994, MediGene AG is a biotechnology company. Prof. Dr. Dolores J. Schendel is the current CEO and Chief Scientific Officer of the company. In 1998, Atlas Venture, Bankhaus Vontobel, Deutsche Bank, Dresdner Bank and Merifin Capital completed a USD 26 million series C round financing of MediGene AG along with returning investors. In 2000, MediGene AG completed an initial public offering of 2.6 million shares at EUR 39.65 each.

The company is developing novel immunotherapies, such as TCR-modified T cells (TCR-Ts) or dendritic cell (DC) vaccines, to treat cancer in areas where there is a significant medical need. Medigene is pursuing a strategy of clinical proof of concept for its own medicinal techniques. In addition, the company provides possibilities for chosen partners to research and develop treatment approaches using its patented technology platforms.

The company intends to continue to evaluate new partnering opportunities related to its portfolio of TCR technologies and product candidates.

## Funding rounds

- Series C, Sep 1, 1998, $26M — Atlas Venture, STAR Ventures, Deutsche Bank, AlpInvest Partners, TVM Capital Life Science, Merifin Capital, Dresdner Bank, Bankhaus Vontobel

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series C
- STAR Ventures — Series C
- Deutsche Bank — Series C
- AlpInvest Partners — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C
- Merifin Capital (https://capitalatlas.ai/funds/merifin-capital) — Series C
- Dresdner Bank — Series C
- Bankhaus Vontobel — Series C